Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C26H28ClNO · C6H8O7
CAS Number:
Molecular Weight:
598.08
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51111800
MDL number:
Quality Level
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to off-white
solubility
DMSO: >10 mg/mL
storage temp.
2-8°C
SMILES string
OC(=O)CC(O)(CC(O)=O)C(O)=O.CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c2ccccc2)\c3ccccc3
InChI
1S/C26H28ClNO.C6H8O7/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21;7-3(8)1-6(13,5(11)12)2-4(9)10/h3-16H,17-20H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;
InChI key
IWEQQRMGNVVKQW-OQKDUQJOSA-N
Gene Information
human ... ESR1(2099), ESR2(2100)
General description
Toremifene is a triphenylethylene derivative. It exhibits antitumor and antiestrogen effects. Toremifene has estrogen-agonist effects on blood lipids and endometrium.
Application
Toremifene citrate salt has been used:
- in cell-based ELISA
- as a positive control to detect its antiviral activity against Ebola virus (EBOV)
- to treat MCF7 and T47D breast cancer cell lines
Biochem/physiol Actions
Toremifene citrate is an oral selective estrogen receptor modulator (SERM). It is used in advanced (metastatic) breast cancer and being evaluated for prevention of prostate cancer. Toremifene citrate is known to increase bone mineral density in prostate cancer patients undergoing androgen deprivation therapy†.
Features and Benefits
This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Preparation Note
Toremifene citrate salt is soluble in DMSO at a concentration that is greater than 10 mg/ml.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Eye Dam. 1
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Lack of effect of lamivudine on Ebola virus replication
Hensley LE, et al.
Emerging Infectious Diseases, 21(3), 550-550 (2015)
Hideaki Ogata et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 40(6), 749-753 (2013-07-19)
Third-generation aromatase inhibitors(AIs)are now common in adjuvant hormone therapy for breast cancer in postmenopausal women. However, a suitable treatment has yet to be established for patients who develop cancer recurrence during or after adjuvant AI therapy. This prospective study evaluated
Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients
Marttunen MB, et al.
The Journal of Clinical Endocrinology and Metabolism, 83(4), 1158-1162 (1998)
Global Trade Item Number
| SKU | GTIN |
|---|---|
| T7204-25MG | 04061837372438 |
| T7204-5MG | 04061837372445 |


